Skip to content

Comparison of the effect of corticosteroids and extracorporeal shockwave therapy in the treatment of pes anserine bursitis

Comparing the efficacy of local corticosteroid injection and Extracorporeal shockwave therapy in patients diagnosed with pes anserine bursitis

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20151123025202N16
Enrollment
60
Registered
2021-07-17
Start date
2021-08-06
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pes anserine bursitis. Other bursitis of knee

Interventions

Intervention 1: Intervention group: Patients in this group will receive extra corporeal shock wave therapy (ESWT). ESWT will be done in one session per week for 3 consecutive weeks. ESWT will be perf
Then, under ultrasound guidance, 40 mg of methylprednisolone and 1 ml of 1% lidocaine will be injected at the marked site.

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Diagnosis of PAB according to clinical and paraclinical criteria by a specialist physician Diagnosis period at least 3 months Age 65-18 years Pain severity greater than 3 according to VAS scale

Exclusion criteria

Exclusion criteria: Comorbidity of other knee diseases such as advanced osteoarthritis, infection and ... History of recent knee surgery or trauma Vascular disease History of corticosteroid therapy during the last 4 months

Design outcomes

Primary

MeasureTime frame
Pes Anserin thickness changes. Timepoint: Before, 1 and 3 month after treatment. Method of measurement: Sonography.;Pain severity. Timepoint: Before, 1 and 3 month after treatment. Method of measurement: Visual Analogues Scale.

Secondary

MeasureTime frame
Patients quality of life. Timepoint: Before, 1 and 3 months after treatment. Method of measurement: Sf-12 questionnaire.;Treatment complications. Timepoint: 1 and 3 months after treatment. Method of measurement: Examination and interview.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbbas Moradi

Hamedan University of Medical Sciences

a.moradi@umsha.ac.ir+98 81 3838 0557

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026